Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL

Blood 2026

View at publisher
Authors: Hrishikesh K. Srinagesh, Vishal Gupta, Amy Zhang, Michael R Grunwald, Matthew P Connor, Vamsi Kota, Jacob Boccucci, M. Ulrickson, Roshini Pradeep, L Hill, Stephanie B. Tsai, TIMOTHY E. O'CONNOR
+56 more Karamjeet Sandhu, Anjali S. Advani, Ran Reshef, Christian Gordillo, Marlise R. Luskin, Evan C. Chen, Chenyu Lin, Ryan D. Cassaday, Noam E. Kopmar, Navneet S. Majhail, Minoo Battiwalla, Stephen A. Strickland, C F Lee, Silvina Odstrcil Bobillo, Talal Hilal, Jae H Park, Yannis K. Valtis, Rawan Faramand, Melhem M Solh, Caitlin Guzowski, Sumithira Vasu, Jessica Leonard, Virginia Tan, Eunice S. Wang, Ross McCauley, Joshua Sasine, Kevin Tang, Miller Kk, Katherine C. Sutherland, Michael Daunov, Razan Mohty, Omer Jamy, Muthu Sendhil Kumaran, Rasmus T. Hoeg, Kaitlyn C. Dykes, Aaron Logan, Tamer Othman, Wendy A Stock, Marc S. Schwartz, Kenneth Byrd, Fevzi Yalniz, Veronika Bachanova, Sean Tracy, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan O. Oluwole, Bhagirathbhai Dholaria, Kristen M O'Dwyer, Jozal Moore, Gregory W. Roloff, Noelle V. Frey, Ibrahim Aldoss, B. D. Shah, Caspian Oliai, Lori Muffly
DOI: 10.1182/blood.2025031734
Cited by: 3
References: 24

Abstract

ABSTRACT: In a real-world analysis of brexucabtagene autoleucel recipients with relapsed/refractory B-cell acute lymphoblastic leukemia (N = 278), lack of response to prior blinatumomab correlates with significantly worse following chimeric antigen receptor T-cell therapy outcomes.

Fields of Study & Subjects

CAR-T cell therapy research Acute Lymphoblastic Leukemia research Chronic Myeloid Leukemia Treatments

Publication details

Journal / source
Blood
Publisher
American Society of Hematology
Volume
147
Issue
17
Pages
2011–2017
Publication date
5 February 2026
Language
EN